Sermorelin has a regulatory history that's genuinely unusual among the peptides on this site: it was, at one point, an FDA-approved drug, which makes its current status worth explaining carefully.
What It Is
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of natural growth hormone releasing hormone (GHRH), the active fragment responsible for stimulating the pituitary gland to release growth hormone. It works through the same natural feedback pathway as the body's own GHRH, rather than introducing growth hormone directly.
Regulatory Status
Sermorelin was FDA-approved under the brand name Geref in the 1990s for diagnostic use and for treatment of growth hormone deficiency in children. The original manufacturer discontinued the branded product for business reasons unrelated to safety findings, and while the underlying FDA approval technically lapsed with that discontinuation, the drug is not currently marketed as an FDA-approved product. Today, sermorelin is most commonly available through compounding pharmacies, since it doesn't carry the same specific compounding restrictions that apply to BPC-157 or TB-500, though compounded sermorelin products aren't individually FDA-approved the way the original Geref product was.
What the Research Shows
Because it did go through the original approval process, sermorelin has a genuine clinical trial history establishing its effects on growth hormone stimulation and its use in diagnosing growth hormone deficiency, more substantial than most compounds discussed elsewhere in this guide series. Its use for adult purposes like anti-aging or body composition, which is how it's commonly marketed through telehealth and compounding channels today, extends well beyond its original approved pediatric and diagnostic indications and hasn't been established through comparable trials for that different population and purpose.
Safety Considerations
Within its original studied population and use, sermorelin's safety profile is relatively well characterized compared to unapproved research chemicals. Its safety for the different doses, durations, and adult populations it's commonly used for today hasn't been established through the same rigorous process, an important distinction between its historical approval and its current, broader marketing.
The Bottom Line
Sermorelin's history as a formerly FDA-approved drug gives it a stronger evidentiary foundation than most peptides on this site, but that foundation was built around a specific pediatric and diagnostic use quite different from how it's commonly marketed and used today, which is worth keeping distinct when evaluating current claims about it.
Why Discontinuation Isn't the Same as Withdrawal for Safety Reasons
It's worth being clear that Geref's discontinuation reflected a business decision by its original manufacturer, not a safety-driven withdrawal by the FDA, an important distinction from a drug pulled from the market due to newly discovered risk. That history is part of why sermorelin has remained a relatively common compounding pharmacy offering despite lacking a currently marketed FDA-approved product, unlike BPC-157 or TB-500, which were affirmatively excluded from compounding specifically due to insufficient safety data.